Skip to Content

Cresemba Approval History

  • FDA approved: Yes (First approved March 6th, 2015)
  • Brand name: Cresemba
  • Generic name: isavuconazonium
  • Dosage form: Capsules and Injection
  • Company: Astellas Pharma US, Inc.
  • Treatment for: Invasive Aspergillosis; Invasive Mucormycosis

Cresemba (isavuconazonium) is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Development History and FDA Approval Process for Cresemba

Mar  6, 2015Approval FDA Approves Cresemba (isavuconazonium sulfate) For Fungal Infections
Jan 22, 2015Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of Cresemba (isavuconazonium)
Nov  3, 2014Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis
Jul  9, 2014Astellas Submits NDA for Isavuconazole Invasive Aspergillosis and Invasive Mucormycosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.